Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group

Current Oncology

Volumn 15, Issue 1, 2008, Pages 24-35

  Mackey, John R ^a   Clemons, Mark ^a   Côté, Marc Andre ^a   Delgado, Diego ^a   Dent, Susan ^a   Paterson, Alexander ^a   Provencher, Louise ^a   Sawyer, Michael B ^a   Verma, Sunil ^a  

^a NONE

Author keywords

Adjuvant chemotherapy; Anthracycline; Cardiotoxicity; Early stage breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARBOPLATIN; CARVEDILOL; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENALAPRIL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LISINOPRIL; NAVELBINE; PACLITAXEL; RAMIPRIL; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BODY MASS; BREAST CANCER; CANADA; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FINLAND; HEALTH CARE PLANNING; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRACTICE GUIDELINE; SIDE EFFECT; VALVULAR HEART DISEASE;

EID: 51649092308     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2008.199     Document Type: Article

References (44)

1. Vainio H, Bianchini F, eds., on behalf of the International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Cancer-preventive Agents. Breast Cancer Screening. Vol. 7. Handbooks of cancer prevention. Lyon, France: IARC Press; 2002.
2. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto: Canadian Cancer Society; 2008.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
5. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-ErbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049-56.
6. Hynes NE, Stern DF. The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
7. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
8. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-74.
9. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002;20: 3106-13.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
11. Baselga J, Carbonell X, Castañeda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71.
12. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26.
13. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
14. Hoffman-La Roche Ltd. Herceptin (Trastuzumab) [product monograph]. Mississauga, ON: Hoffman-La Roche; October 2006.
15. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 2007;7:600-7.
16. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-9.
17. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006;11(suppl 1):4-12.
18. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
19. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract 512]. Proc Am Soc Clin Oncol 2007;25:.
20. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [slides]. Presented at the San Antonio Breast Cancer Symposium; San Antonio, TX; December 14-17, 2006. [Available online at: www.bcirg.org/NR/rdonlyres/ eqkdodg2dy7t557o7s6uvj7ytpe6gcfg5gmh2ely6hnhh5 pjlabz3nd6jddlnao7qoikej3edohsijyiisfvp367uuc/BCIRG006 +2nd+Interim+Analysis.pdf; cited January 24, 2008]
21. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23-45. [Erratum in: Can J Cardiol 2006;22:271]
22. Heart Failure Society of America (HFSA). Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12:10-38.
23. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
24. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 2007;25:3859-65.
25. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
26. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction in NSABP B-31: a randomized trial of AC→paclitaxel vs AC→paclitaxel with trastuzumab in HER2-positive, node-positive, operable breast cancer [abstract LBA513]. Proc Am Soc Clin Oncol 2007;25:.
27. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract 1]. Breast Cancer Res Treat 2005;94(suppl 1):.
28. Hind D, Pilgrim H, Ward S. Questions about adjuvant trastuzumab s] still remain. Lancet 2007;369:3-5.
29. Lefrak E, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973; 32:302-14.
30. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23:2900-2.
31. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31.
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy rn HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
33. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-19.
34. Geyer CE, Bryant JL, Romond EH, et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→paclitaxel (T) VS AC → T with trastuzumab (H) [abstract 581]. Proc Am Soc Clin Oncol 2006;24:.
35. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
36. Halyard MY, Pisansky TM, Solin LJ, et al. Adjuvant radiotherapy and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group phase 3 trial N9831 [abstract 523]. Proc Am Soc Clin Oncol 2006;24:.
37. Perez EA, Suman VJ, Davidson NE, et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial [abstract 556]. Proc Am Soc Clin Oncol 2005;23:.
38. Trudeau M, Madarnas Y, McCready D, Pritchard KI, Messersmith H, on behalf of the Breast Cancer Disease Site Group. The role of trastuzumab in adjuvant and neoadjuvant therapy in women with HER2/ neu-overexpressing breast cancer: a clinical practice guideline, section 1. Evidence-based series 1-24. Hamilton, ON: Cancer Care Ontario, Program in Evidence-Based Care; January 25, 2007.
39. British Columbia Cancer Agency (BCCA). BC Cancer Agency > Health Professionals Info > Cancer Management Guidelines > Breast > 6. Management > 041 Adjuvant Trastuzumab Therapy [Web page]. Vancouver: BCCA; January 24, 2006. [Available at: www.bccancer.bc.ca/HPI/ CancerManagementGuidelines/Breast/Management/ 041+Adjuvant+Trastuzumab+Therapy.htm; cited October 1, 2007]
40. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Ver. 2.2007. Fort Washington, PA: NCCN; March 28, 2007. [Available online at: www.nccn.org/ professionals/physician_gls/PDF/breast.pdf; cited October 1, 2007]
41. Comité de l'évolution des pratiques en oncologie (CÉPO). Guide d'utilisation du trastuzumab (Herceptin) dans le traitement adjuvant du cancer du sein. Québec, QC: Santé et Services sociaux Québec; July 2005.
42. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, on behalf of the 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44. [Erratum in: Ann Oncol 2007; 18:1917]
43. Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007; 23:21-45.
44. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6.